PVLA
NASDAQ · Biotechnology
Palvella Therapeutics Inc
$175.92
+19.07 (+12.16%)
Financial Highlights (FY 2026)
Revenue
547.08M
Net Income
-109,696,002
Gross Margin
—
Profit Margin
-57.3%
Rev Growth
+13.4%
D/E Ratio
0.63
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 35.1% | 35.1% |
| Operating Margin | -69.5% | -62.6% | 16.9% | 20.8% |
| Profit Margin | -57.3% | -54.5% | 16.5% | 14.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 547.08M | 482.27M | 158.95M | 134.45M |
| Gross Profit | — | — | 55.78M | 47.18M |
| Operating Income | -380,278,243 | -301,701,709 | 26.92M | 27.98M |
| Net Income | -109,696,002 | -87,029,620 | 26.26M | 18.87M |
| Gross Margin | — | — | 35.1% | 35.1% |
| Operating Margin | -69.5% | -62.6% | 16.9% | 20.8% |
| Profit Margin | -57.3% | -54.5% | 16.5% | 14.0% |
| Rev Growth | +13.4% | +13.4% | +20.5% | +20.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 491.43M | 491.43M | 243.86M | 257.74M |
| Total Equity | 774.27M | 774.27M | 493.28M | 509.61M |
| D/E Ratio | 0.63 | 0.63 | 0.49 | 0.51 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -90,337,714 | -75,653,057 | 46.23M | 40.75M |
| Free Cash Flow | — | — | 10.92M | 9.19M |